You are here

  • Home
  • Online First
  • Hormone therapy not recommended for chronic disease prevention in menopausal women

Article Text

Article menu

other Versions

Download PDFPDF
Prevention
Systematic review
Hormone therapy not recommended for chronic disease prevention in menopausal women
  1. Nanette K Wenger
  1. Department of Medicine (Cardiology), Emory University School of Medicine, Atlanta, Georgia, USA
  1. Correspondence to : Dr Nanette K Wenger
    Department of Medicine (Cardiology), Emory University School of Medicine, 49 Jesse Hill Jr. Drive, SE Atlanta, GA 30303, USA; nwenger{at}emory.edu

https://doi.org/10.1136/eb-2012-100992

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Nelson HD, Walker M, Zakher B, et al. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the US Preventive Services Task Force recommendations. Ann Intern Med 2012;157:104–13.OpenUrlCrossRefPubMedWeb of Science

    Context

    In 2005, the US Preventive Services Task Force (USPSTF) updated its 2002 hormone replacement therapy recommendations, advising against the routine use of oestrogen and progestin (E+P) and unopposed oestrogen (E) to prevent chronic conditions in menopausal women. Menopausal hormone therapy (MHT) had been commonly prescribed to prevent conditions such as cardiovascular disease, dementia and osteoporosis. Clinical trial data dramatically changed clinical practice. The Heart and Estrogen/Progestin Replacement Study (HERS) examined conjugated equine oestrogen (CEE)+medroxyprogesterone acetate in women with coronary disease; hormone therapy did not decrease coronary events. Primary prevention was studied in the Women's Health Initiative (WHI) trial: E+P or E in women with …

    View Full Text

    Footnotes

    • Competing interests None.